Technology

The efforts to create RDC (Radionuclide Drug Conjugate) in Rdcthera benefit from our advanced RDC development and analysis platforms that are dedicated to providing our customers with high-quality products, customized services, analytical testing services, and expert consulting for RDC development projects.

Introduction into RDC

• Background of RDC
  In the past decades, oncology is a research hotspot. With the discovery of targeted molecules, such as antibodies, small molecules, and peptides, precise treatment for cancer becomes possible. Nuclear medicine is widely used in the clinical treatment of cancer since the early 2000s. However, in general radiotherapy, the alpha-emitting radionuclides can cause great damage to the healthy parts of the patients. Notably, with targeted molecules combined with a radionuclide, the bifunctional RDC is capable to conduct diagnosis and treatment in one step, termed targeted alpha therapy (TAT).

Fig.1 Illustration of TAT. (Kitson, S. L. et al., 2014, Cancer Stud Mol Med Open J)

• Advantages of RDC
  Combining two functional components, including targeting molecule and radionuclide, RDC brings together many advantages in clinical utilization.

• Damage cancer cells precisely with minimal damage to healthy cells
• Integrating therapeutic and diagnostic imaging roles in one
• Flexibly designing to address different types of tumors

To support RDC development for worldwide clients, Rdcthera has established a professional RDC development platform to support high-quality RDC-related services.

RDC Design and Synthesis

RDC Conjugation

RDC Analysis Service

Chemical Development

The scientists in Rdcthera have wealthy training and experience in synthetic chemistry, analytical chemistry, process chemistry, process safety, and engineering. Our chemical development group is fitted with fume hoods in multiple suites to support robust and safe processes for manufacturing and is also equipped with new-age technologies such as chemical synthesis and conjugation technology, software-based toxicity evaluation, quantitative risk assessment, and green chemistry to support our synthesis services for chemical molecules and chelators, as well as our conjugation services.

Biomolecular Screening

To ensure specificity and efficacy, Rdcthera utilize comprehensive antibody, small molecule, and peptide libraries, along with our well-established phage display platform and other affinity evaluation technology, such as surface plasmon resonance (SPR) technology and isothermal titration calorimetry (ITC) technology, to perform extensive screening that helps identify suitable targeting vector for specific target recognition. Combined with our significant bioconjugation expertise and proven platform technology will efficiently turn your materials into an RDC, enable scaling, and shorten your path to the clinic.

Radionuclide Screening and Synthesis

The scientists in Rdcthera have wealthy training and experience in synthetic chemistry, analytical chemistry, process chemistry, process safety, and engineering. Our chemical development group is fitted with fume hoods in multiple suites to support robust and safe processes for manufacturing and is also equipped with new-age technologies such as chemical synthesis and conjugation technology, software-based toxicity evaluation, quantitative risk assessment, and green chemistry to support our synthesis services for chemical molecules and chelators, as well as our conjugation services.

Pre-Clinical Studies

Rdcthera has an excellent pre-clinical group founded by a number of professional and experienced experts. We offer preclinical testing of RDC products using standardized and validated preclinical platforms based on cancer cell lines and cancer beard mouse models, closely recapitulating human pathologies.

Combining all of our excellent groups, Rdcthera can provide one-step and customized RDC-related services for worldwide clients with premium quality in a short time. If you are interested in our excellent RDC-related platform and technology, please contact us for more information.

Reference

1. Kitson, S. L. (2014). Application of Radionu-clides and Antibody-Drug Conjugates to Target Cancer. Cancer Stud Mol Med Open J, 1(1), 1-7.